Do A, Zahrawi F, Mehal W
Nat Rev Drug Discov. 2024; 24(3):171-189.
PMID: 39609545
DOI: 10.1038/s41573-024-01084-2.
Hudson D, Afzaal T, Bualbanat H, AlRamdan R, Howarth N, Parthasarathy P
Therap Adv Gastroenterol. 2024; 17:17562848241276334.
PMID: 39553445
PMC: 11565685.
DOI: 10.1177/17562848241276334.
Harvey B
Acta Pharmacol Sin. 2024; 46(3):515-524.
PMID: 39511464
PMC: 11845757.
DOI: 10.1038/s41401-024-01396-4.
Tan Y, Zhang X
Ann Med. 2024; 56(1):2420858.
PMID: 39460547
PMC: 11514388.
DOI: 10.1080/07853890.2024.2420858.
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I
J Pathol Clin Res. 2024; 10(5):e12395.
PMID: 39294925
PMC: 11410674.
DOI: 10.1002/2056-4538.12395.
Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology.
Naoumov N, Kleiner D, Chng E, Brees D, Saravanan C, Ren Y
Liver Int. 2024; 44(12):3214-3228.
PMID: 39248039
PMC: 11586893.
DOI: 10.1111/liv.16092.
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.
Ciardullo S, Muraca E, Vergani M, Invernizzi P, Perseghin G
Gastroenterol Rep (Oxf). 2024; 12:goae029.
PMID: 38681750
PMC: 11052658.
DOI: 10.1093/gastro/goae029.
ASK1/ p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
Peng Z, Wei G, Huang P, Matta H, Gao W, An P
Hepatology. 2024; 80(2):346-362.
PMID: 38377458
PMC: 11477174.
DOI: 10.1097/HEP.0000000000000801.
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review.
Tun K, Noureddin N, Noureddin M
Clin Liver Dis (Hoboken). 2023; 22(3):103-112.
PMID: 37799634
PMC: 10550044.
DOI: 10.1097/CLD.0000000000000066.
Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests.
Boursier J, Roux M, Costentin C, Chaigneau J, Fournier-Poizat C, Trylesinski A
Nat Commun. 2023; 14(1):5219.
PMID: 37633932
PMC: 10460420.
DOI: 10.1038/s41467-023-40328-4.
Challenges and opportunities in NASH drug development.
Harrison S, Allen A, Dubourg J, Noureddin M, Alkhouri N
Nat Med. 2023; 29(3):562-573.
PMID: 36894650
DOI: 10.1038/s41591-023-02242-6.
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.
Meyer E, Mesenbrink P, Di Prospero N, Pericas J, Glimm E, Ratziu V
PLoS One. 2023; 18(3):e0281674.
PMID: 36893087
PMC: 9997886.
DOI: 10.1371/journal.pone.0281674.
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.
Noureddin M, Goodman Z, Tai D, Chng E, Ren Y, Boudes P
Aliment Pharmacol Ther. 2023; 57(4):409-417.
PMID: 36647687
PMC: 10107331.
DOI: 10.1111/apt.17363.
NAFLD in Indians: A Myopic Yet Alarming Perspective.
Singh S, Anirvan P
J Clin Exp Hepatol. 2023; 13(1):7-9.
PMID: 36647401
PMC: 9840069.
DOI: 10.1016/j.jceh.2022.11.016.
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis.
Jacobson I, Wong V, Castera L, Anstee Q, Noureddin M, Cusi K
J Clin Gastroenterol. 2022; 57(3):253-264.
PMID: 36251413
PMC: 9911115.
DOI: 10.1097/MCG.0000000000001780.
Histological assessment based on liver biopsy: the value and challenges in NASH drug development.
Tong X, Wang Q, Zhao X, Sun Y, Wu X, Yang L
Acta Pharmacol Sin. 2022; 43(5):1200-1209.
PMID: 35165400
PMC: 9061806.
DOI: 10.1038/s41401-022-00874-x.
NASH: regulatory considerations for clinical drug development and U.S. FDA approval.
Harvey B
Acta Pharmacol Sin. 2022; 43(5):1210-1214.
PMID: 35110697
PMC: 9061714.
DOI: 10.1038/s41401-021-00832-z.
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.
Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J
Nat Med. 2021; 27(10):1825-1835.
PMID: 34621052
DOI: 10.1038/s41591-021-01495-3.
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.
Shi Y, Yang R, Fan J
World J Gastroenterol. 2021; 27(26):3971-3983.
PMID: 34326608
PMC: 8311534.
DOI: 10.3748/wjg.v27.i26.3971.
Redefining therapeutic success in HIV patients: an expert view.
Antela A, Rivero A, Llibre J, Moreno S
J Antimicrob Chemother. 2021; 76(10):2501-2518.
PMID: 34077524
PMC: 8446931.
DOI: 10.1093/jac/dkab168.
